Dr. Whitfield Board Growdon, MD

Dr. Growdon practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Growdon's NPI, 1669530481, was assigned on December 5, 2006. Dr. Growdon holds New York license 313314.

Dr. Growdon's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Growdon's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Growdon is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Growdon to 1 more hospital, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Growdon practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Growdon's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Growdon's licenses on file in 2 states: New York and Massachusetts.

CMS data shows 285 Medicare services from Dr. Growdon across 5 procedure codes in 2024, for 110 Medicare patients. Medicare paid $23,584 for them.

CMS counts 110 Medicare patients who saw Dr. Growdon in 2024. The largest group is 65 to 74, with 60 patients. 69% of them have high cholesterol, and 56% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Growdon's median patient age at 62, with 96% women.

In 2024, Dr. Growdon wrote 44 Medicare Part D claims for 21 patients. 100% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $166 in total drug cost. In 2021, CMS named 42 claims across 2 drugs.

Dr. Growdon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Growdon as offering telehealth. CMS counts 23 procedures of removal of the uterus by Dr. Growdon, more than 94% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 98 papers to Dr. Growdon, published from 2010 to 2024. 2020 was the busiest year, with 9. The most frequent topics are Ovarian Neoplasms, Endometrial Neoplasms and Carcinoma, Endometrioid. Dr. Growdon has published most often in Gynecol Oncol. Dr. Growdon's most frequent co-authors are Annekathryn Goodman, MD, John Orland Schorge, MD and Ross Stuart Berkowitz, MD.

Dmand AI links Dr. Growdon to 1 clinical trial. 1 is still active or recruiting.

CMS Open Payments shows 29 general payments to Dr. Growdon from 11 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 75% of the total. GlaxoSmithKline, LLC. paid the most, $11,588.